Description
ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3]